Symbols

ERNA

Ernexa·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Ample Liquidity

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ERNA

Ernexa Therapeutics Inc.

A biopharmaceutical company that developing transformational new medicines

Industry

Biological Technology

Established Date

Listing Date

10/25/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ernexatx.com

Security Type

Common stock

Office address

10355 Cambridge Street, Suite 18A, Cambridge, MA 02141

Business

Introduction

Ernexa Therapeutics Inc was incorporated in Delaware in 1984. Ernexa is an advanced clinical-stage biopharmaceutical company focused on IL-2 cytokine based therapies for the treatment of cancer patients. Ernexa is committed to the development of IRX-2, a novel cytokine-based therapy for the treatment of cancer patients. IRX-2 active ingredients, namely IL-2 and other key cytokines, are assumed to signal, enhance and restore immune function suppressed by tumors, enabling the immune system to attack cancer cells.

Company Financials

EPS

ERNA has released its 2025 Q2 earnings. EPS was reported at -0.61, versus the expected 0, missing expectations. The chart below visualizes how ERNA has performed over recent quarters, highlighting trends in earnings surprises.